You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Adenovirus 5, HIV, COVID19, vaccine

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Covid19 Trial in Caba, Capital Federal (Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV))

Recruiting
  • Covid19
  • Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)
  • Caba, Buenos Aires, Argentina
  • +3 more
Sep 14, 2021

COVID-19 Trial in Wuhan (Prototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine(Adenovirus Type 5 Vector) For

Recruiting
  • COVID-19
  • Prototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine(Adenovirus Type 5 Vector) For Inhalation
  • +2 more
  • Wuhan, Hubei, China
    Zhongnan Hospital of Wuhan University
Jun 1, 2023

COVID-19 Trial (1 Nebulized inhalation for booster groups, 2 Nebulized inhalation for booster groups, 3 Nebulized inhalation for

Recruiting
  • COVID-19
  • 1 Nebulized inhalation for booster groups
  • +23 more
  • Xiangxi, Hunan, China
    CDC of of Luxi County, Xiangxi Tujia and Miao Autonomous Prefect
Oct 24, 2022

COVID-19 Trial in Taizhou (Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Recombinant Novel Coronavirus

Completed
  • COVID-19
  • Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
  • Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo
  • Taizhou, Jiangsu, China
    Taixing City center for Disease Control and Prevention
Oct 28, 2022

COVID-19 Trial in Yancheng (Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml, Recombinant Novel

Active, not recruiting
  • COVID-19
  • Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml
  • Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml
  • Yancheng, Jiangsu, China
    Funing Center for Disease Control and Prevention
Oct 28, 2022

Immunogenicity and Safety of a Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine Using for Sequential Immunization Trial

Recruiting
  • Immunogenicity and Safety of a Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine Using for Sequential Immunization
  • Recombinant adenovirus type-5-vectored COVID-19 vaccine
  • Hangzhou, Zhejiang, China
    Xihu District Center for Disease Control and Prevention
May 12, 2022

Adenovirus Type-5 Vectored COVID-19 Vaccine Trial in Wuhan (Adenovirus Type-5 Vectored COVID-19 Vaccine)

Completed
  • Adenovirus Type-5 Vectored COVID-19 Vaccine
  • Adenovirus Type-5 Vectored COVID-19 Vaccine
  • Wuhan, Hubei, China
    A rehabilitation centre in Wuhan
Mar 28, 2022

COVID-19 Trial in Singapore (Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation)

Not yet recruiting
  • COVID-19
  • Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation
  • Singapore, Singapore
    National University Hospital
Jan 29, 2023

COVID-19 Trial (Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector), Bivalent Recombinant COVID-19 Vaccine

Not yet recruiting
  • COVID-19
  • Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)
  • +2 more
  • (no location specified)
Jul 5, 2022

COVID-19 Trial (Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH), Placebo)

Not yet recruiting
  • COVID-19
  • Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)
  • Placebo
  • (no location specified)
Nov 19, 2021

COVID-19 Trial in South Africa (Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer))

Recruiting
  • COVID-19
  • Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)
  • Pretoria, Gauteng, South Africa
  • +4 more
Aug 23, 2022

COVID-19 Trial (High dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell), Low dose of Recombinant

Not yet recruiting
  • COVID-19
  • High dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)
  • +3 more
  • (no location specified)
Jun 19, 2023

COVID-19, SARS-CoV-2 Acute Respiratory Disease Trial in Spain (COVID-19 Vaccine HIPRA 40 ug/dose, Comirnaty (Pfizer-BioNtech) 30

Recruiting
  • COVID-19
  • SARS-CoV-2 Acute Respiratory Disease
  • COVID-19 Vaccine HIPRA 40 ug/dose
  • Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection
  • Coruña, Spain
  • +6 more
Jul 21, 2022

COVID-19 Trial in Nanjing (Ad5-nCoV-IH, Ad5-nCoV-IM, CoronaVac)

Active, not recruiting
  • COVID-19
  • Ad5-nCoV-IH
  • +2 more
  • Nanjing, Jiangsu, China
    Jiangsu Provincial Center for Diseases Control and Prevention
Aug 12, 2022

COVID-19 Trial (Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells), Placebo)

Not yet recruiting
  • COVID-19
  • Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)
  • Placebo
  • (no location specified)
Sep 22, 2023

HIV, Organ Transplantation, Lymphoma, Non-Hodgkin Trial in Melbourne (Pfizer Bivalent COVID-19 Vaccine, Moderna Bivalent mRNA

Recruiting
  • HIV
  • +5 more
  • Pfizer Bivalent COVID-19 Vaccine
  • Moderna Bivalent mRNA vaccine
  • Melbourne, Victoria, Australia
    Alfred Health
Jan 31, 2023

Vaccine Reaction, COVID-19 Trial in Paris (Comirnaty® BNT162b2 /Omicron BA.4-5 vaccine (Pfizer-BioNTech), VidPrevtyn® Beta

Not yet recruiting
  • Vaccine Reaction
  • COVID-19
  • Comirnaty® BNT162b2 /Omicron BA.4-5 vaccine (Pfizer-BioNTech)
  • VidPrevtyn® Beta vaccine (Sanofi/GSK)
  • Paris, France
    CIC 1417 Cochin-Pasteur
Feb 28, 2023

COVID-19 Trial in Paris (Lymph node aspiration / Blood sampling)

Recruiting
  • COVID-19
  • Lymph node aspiration / Blood sampling
  • Paris, France
    GH Broca-Cochin-Hôtel-Dieu CIC 1417 Cochin-Pasteur
Jul 19, 2023

COVID-19 Trial in Lianyungang (batch 1 of Ad5-nCoV, batch 2 of Ad5-nCoV, batch 3 of Ad5-nCoV)

Completed
  • COVID-19
  • batch 1 of Ad5-nCoV
  • +2 more
  • Lianyungang, Jiangsu, China
    Guanyun Center for Disease Control and Prevention
Apr 5, 2022

COVID-19 Trial (Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Recombinant COVID-19 vaccine (adenovirus type

Not yet recruiting
  • COVID-19
  • Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
  • Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)
  • (no location specified)
Jan 11, 2022

COVID-19, SARS-CoV2 Infection Trial in Hamilton (Ad5-triCoV/Mac, ChAd-triCoV/Mac)

Recruiting
  • COVID-19
  • SARS-CoV2 Infection
  • Ad5-triCoV/Mac
  • ChAd-triCoV/Mac
  • Hamilton, Ontario, Canada
    McMaster University Medical Centre
Jun 15, 2022

COVID-19 Trial in Nanjing (recombinant Ad5 vectored COVID-19 vaccine, RBD-based protein subunit vaccine (ZF2001) against

Completed
  • COVID-19
  • recombinant Ad5 vectored COVID-19 vaccine
  • +2 more
  • Nanjing, Jiangsu, China
    Jiangsu Provincial Center for Diseases Control and Prevention
Mar 28, 2022

COVID-19 Trial in Nanjing (Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation, Recombinant Novel

Recruiting
  • COVID-19
  • Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation
  • +3 more
  • Nanjing, Jiangsu, China
    Jiangsu Provincal Center for Disease Control and Prevention
Jul 27, 2021

COVID-19 Trial in Nanjing (Intramuscularly administered Ad5-nCoV vaccine, Aerosolized Ad5-nCoV, DelNS1-2019-nCoV-RBD-OPT1)

Not yet recruiting
  • COVID-19
  • Intramuscularly administered Ad5-nCoV vaccine
  • +3 more
  • Nanjing, Jiangsu, China
    Jiangsu Provincial Center for Disease Control and Prevention
May 10, 2023

HIV Trial in United States (MRKAd5 HIV-1 gag/pol/nef)

Completed
  • HIV Infections
  • MRKAd5 HIV-1 gag/pol/nef
  • Birmingham, Alabama
  • +3 more
Oct 13, 2021